Stanford Alzheimer's Disease Research Center Clinical Trials and Research Studies

Studies directly supported by the ADRC

Healthy Brain Aging Study

This is a longitudinal study enrolling individuals with Alzheimer’s disease, Mild Cognitive Impairment, Lewy Body Dementia, Parkinson’s disease, Parkinson’s disease with dementia and healthy volunteers. It is funded by the National Institute of Health and is part of the Alzheimer’s Disease Research Center (ADRC). This study will collect data including medical history, family history and medication. There will be questionnaires to be filled out, cognitive testing and PET/MRI of the brain. This study will follow participants over time.
Status:
Active recruiting
PI:
Victor Henderson, MD
Status: Open, enrollment ongoing
Research coordinator: Christina Wyss-Coray
CWyssCoray@stanfordhealthcare.org
650-721 2409

Pacific Udall Center

Sponsor: NIH/NINDS Morris K. Udall Center of Excellence for Parkinson's Disease Research
PI: Tom Montine, MD, PhD
Study status: Open, Enrollment ongoing
Research coordinator: Maria-Lucia Campos
udallcenter@stanford.edu

(650) 721-5351

Other studies directed by ADRC-affiliated faculty

Tau PET brain imaging in Parkinson’s disease

Sponsor: NIH/NINDS
PI: Kathleen Poston, MD, MS
Study Status: Actively recruiting
Research coordinator: Marian Shahid, MSc
mshahid@stanford.edu 650-723-0060 

Parkinson’s Disease Facial Expression Biomarker Study

Sponsor: The Michael J. Fox Foundation for Parkinson’s disease Research
PI: Kathleen Poston, MD, MS
Study status: Actively recruiting
Research coordinator:
Kristen Wheeler
kjwheele@stanford.edu (650) 269-0484

Iron as an Imaging Biomarker for Inflammation in Alzheimer’s Disease

The purpose of this study is to learn how iron is potentially involved in Alzheimer’s disease.  We are enrolling individuals with Alzheimer’s disease, individuals with Mild Cognitive Impairment, and healthy volunteers.  You will be asked to complete a 7T MRI and a PET-MRI.
Sponsor:
NIH, GE Healthcare
Status:
Open, enrollment ongoing
PI:
Michael Zeineh, MD
Research Coordinator:
Nicole Mouchawar
nmouchaw@stanford.edu 650-260-3026

Clinical Trials

Sponsor: NIA (PEACE-AD)
Intervention
: Prazosin (alpha-1 adrenoreceptor antagonist)
Indication
: probable or possible AD and disruptive agitation
Disruptive Agitation: Any combination of the following behaviors, a) irritability, b) physically and/or verbally aggressive behavior, c) physically resistive to necessary care, and/or d) pressured motor activity (e.g., pressured pacing), occurred nearly daily during the previous week and at least intermittently for 4 weeks prior to screening
Brief Summary:
This is a Phase IIb multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of prazosin in approximately 186 participants with Alzheimer’s disease (AD) complicated by disruptive agitation residing in an LTC or in the home with full-time caregiving.
Clinicaltrials.gov identifier:
NCT03710642
PI
: Victor Henderson, MD and Sharon Sha, MD
Contact
: Amanda Ng - amandang@stanford.edu - (650) 485-9560

Sponsor: Genentech/Roche (Digital Biomarker)
Intervention
: None
Indication
: Healthy controls, Subjective cognitive decline, prodromal and mild-AD
MMSE
: 24-30
Brief Summary:
A prospective pilot study to evaluate the feasibility of conducting smartphone-based remote self-assessments of cognition, function, and behavior in individuals with subjective cognitive decline, early Alzheimer’s disease, and healthy controls.
PI
: Sharon Sha, MD
Contact
: Viktoriya Bourakova - viktoriya.bourakova@stanford.edu - (650) 709-9041

Sponsor: Eisai and NIH (AHEAD 3-45 Study)
Intervention
: BAN2401 (monoclonal antibody binding to amyloid)
Indication
: Pre-clinical AD
MMSE
: 27-30
Brief
Summary: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (A3 Trial)
Clinicaltrials.gov identifier:
NCT04468659
PI
: Sharon Sha, MD
Contact
: Amanda Ng  amandang@stanford.edu  (650) 485-9560
and Anthony Velasquez  anthgv@stanford.edu  650-206-0963

Sponsor: Indiana University and NIA (LEADS)
Intervention
: N/A - Observational
Indication
: Early onset Alzheimer's Disease (EOAD), Early onset non-Alzheimer's Disease (EO-nonAD), and cognitively normal (CN)
Brief
Summary: A non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EO-nonAD) participants, and (3) cognitively normal (CN) control participants.
Clinicaltrials.gov identifier:
NCT03507257
PI
: Sharon Sha, MD
Contact
: Tricia Cunningham - tcunningham@stanford.edu – 650-388-8675